Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

November 16, 2023
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

November 15, 2023
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

November 13, 2023
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 09, 2023
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

November 06, 2023
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

October 30, 2023
Chemomab Therapeutics to Present at Upcoming Scientific Conferences

October 26, 2023
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

September 28, 2023
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 29, 2023
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

August 14, 2023